Before anything else
The filed numbers show a company whose revenue has fallen roughly two-thirds from its 2020 peak, is burning through more cash than it earns, and posted a net loss in the most recent full year. The market is pricing the stock at a price-to-sales multiple sitting in the 97th percentile of its own decade, meaning the market is paying more relative to revenue today than it has almost any other time in the past ten years. Those two readings cannot both be right, and that disagreement is the story.
The COVID windfall that wasn’t really Opko’s
Opko Health built its identity as a hybrid: part diagnostics lab, part specialty pharma, part pipeline bet. For a few years that mix looked inspired. Its BioReference diagnostics arm ran COVID-19 tests by the millions, and the 2020 annual filing showed strong revenue and a positive net margin. Then the tests stopped. By the fiscal year ended December 2024, revenue had collapsed to less than four in every ten dollars of the 2020 figure. The COVID money was never really Opko’s to keep; it was a rental that the pandemic handed back.
That history matters because the stock’s current valuation, a price-to-sales ratio of 7.8 against a decade median of 5.7 per our data, is the mood the market is in. The mood says the business is worth more per dollar of sales today than it was during most of the decade, including the years when it was actually growing. The math, meaning what the filed numbers justify, says something quieter.
What the most recent quarter actually shows
The 10-Q for the quarter ended June 30, 2026 is the most recent filing as of today. The company recorded an operating loss for the quarter. Buried inside the revenue figure is a one-time item worth noticing: a substantial payment came from an intellectual property transfer tied to a new agreement with Nicoya to commercialize Rayaldee in Greater China. Strip that out and the underlying quarterly run-rate looks considerably thinner.
The pharmaceutical segment did something real in the quarter, growing roughly 60% year-over-year, driven partly by international volume and partly by that China licensing payment. The diagnostics arm, BioReference, swung from a sizable operating loss in the same quarter a year earlier to a modest operating profit, a genuine reversal achieved by selling the oncology testing assets to Labcorp in September 2025 and cutting costs aggressively. A business that stops losing money is not the same as a business that starts making it at scale, but the direction changed.
One quarter of diagnostic profitability and a licensing payment that won’t repeat every quarter are meaningful data points in the filed record, but they do not yet constitute a trend.
The cash burn behind the headline
Opko carried $314.4 million in cash at the end of June, which sounds comfortable until the debt sits next to it. Total debt stood at $349.1 million, meaning the cash pile is slightly smaller than what the company owes. Net cash used in operating activities for just the first six months of 2026 was substantial. Think of it this way: a household with savings just barely smaller than its mortgage, and spending meaningfully more than it earns every month, is not in crisis, but it is on a clock.
The company added to that debt in August 2026, issuing $125 million in senior secured notes tied to royalty interests from mazdutide, a drug it doesn’t yet sell in the U.S. That is a bet on future royalties used to fund present operations, which is a legitimate financing tool but one that pledges tomorrow’s upside to pay today’s bills.
The guidance gap
Management raised its full-year 2026 revenue guidance on the July 27 earnings call to a range implying roughly a tripling of what the company reported for full-year 2024. The filed FY2025 result, per the 10-K for fiscal year ended December 2025, showed revenue with a net margin deeply in the red. So the guidance implies an enormous step-up in the second half of 2026, one that the first-half filing has not yet confirmed.
The guidance is management’s stated expectation, not a filed result. The math we can verify is the history; the mood is partly priced on the forecast. That gap is where the risk lives.
What the price-to-sales ratio is quietly assuming
A price-to-sales ratio, the simplest version of a “multiple,” is just the price tag the market puts on each dollar of annual revenue. At 7.8 times, per our data, Opko’s ratio sits at the 97th percentile of its own decade. The stock is priced as if the revenue recovery is not only real but durable and large, because a high multiple on a small revenue base is the market saying “this revenue is going to grow a lot.”
The filed record since 2020 is a revenue line that fell steeply over five years, with one year of modest recovery. The ModeX Therapeutics acquisition in May 2022, paid for with a large slug of Opko stock, added pipeline but not yet revenue. At the Wells Fargo Healthcare Conference in September 2026, management described the company’s direction as a shift toward therapeutics through ModeX, with several clinical programs planned by year-end. Clinical programs are not products. They are expensive promises.
As of October 3, 2026, MarketBeat reported that sell-side analysts had converged on a consensus rating, with an average analyst price estimate in the low single digits, a data point that reflects how the analyst community is currently reading the same filed numbers discussed here. The stock has given back ground over the past year even as a more recent bounce suggests the market is oscillating rather than trending.
Reading the numbers
- Revenue, FY2020 to FY2025: Fell from $495 million to $148 million over five years, per the FY2025 10-K. That is a loss of seven in every ten revenue dollars. A shop that once sold $10 worth of goods now sells $3. The recovery implied by 2026 guidance would need to get back to roughly $6, in one year.
- Q2 2026 operating loss of $7.0 million: Filed in the June 2026 10-Q. Revenue came in, costs came in higher. Think of a restaurant that grossed $164,000 in a quarter but spent $171,000 running the place.
- Price-to-sales of 7.8, at the 97th percentile of the decade: Per our data. A multiple is the price tag per dollar of earnings or sales. Paying 7.8 times sales means paying $7.80 for every $1 the company currently brings in. The decade median is $5.70 for the same dollar. The market is paying a premium that the revenue trend has not yet earned.
- Cash of $314.4 million vs. debt of $349.1 million: Filed in the June 2026 10-Q. The cash covers the debt almost dollar for dollar, but operating activities consumed $62.8 million in just six months. At that pace, the cushion shrinks faster than it looks.
Sources
- 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K, fiscal year ended December 31, 2024 (SEC EDGAR)
- 10-K, fiscal year ended December 31, 2023 (SEC EDGAR)
- Opko Health Q2 2026 press release
- Q2 2026 earnings call transcript (Investing.com)
- ModeX Therapeutics acquisition press release (Opko.com)
- Analyst consensus rating, October 3, 2026 (MarketBeat)
- DirectorsTalk Interviews, September 29, 2026
